EU starts real-time review of AstraZeneca COVID-19 antibody cocktail By Reuters
© Reuters. FILE PHOTO: The logo for AstraZeneca is seen outside its North America headquarters in Wilmington, Delaware, U.S., March 22, 2021. REUTERS/Rachel Wisniewski
(Reuters) -Europe’s drug regulator said on Thursday it had started a real-time review of the antibody-based COVID-19 therapy developed by AstraZeneca (NASDAQ:), roughly a week after the Anglo-Swedish drugmaker sought emergency approval from U.S. authorities.
The decision to begin the assessment by the human medicines committee of the European Medicines Agency (EMA) was based on early results from clinical studies, the regulator said in a statement https://www.ema.europa.eu/en/news/ema-starts-rolling-review-evusheld-tixagevimab-cilgavimab, without specifying when a conclusion was expected.
The medicine, the first protective shot other than vaccines against COVID-19, has proven to work in the non-infected and was also shown to save lives and prevent severe disease when given as treatment within a week of first symptoms.
“EMA will evaluate more data on the quality, safety and effectiveness of the medicine as they become available,” the watchdog said, adding that the rolling review would continue until AstraZeneca submits a formal application for approval.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Nasdaq, S&P 500 end lower, dragged down by communications services By Reuters
© Reuters. Traders work on the floor of the New York Stock Exchange (NYSE) in New York City, U.S., October…
German solar car firm Sono Motors files for U.S. IPO By Reuters
© Reuters. Solar cell panels are seen on the hood of German solar car company Sono Motors’ prototype car “Sion”…